2011 sales: $655 million (actual)
Maker: Boston Scientific ($BSX)
Back story: Licensed from Abbott Laboratories (which sells under the Xience name), Promus sales in 2011 represent a big decline from 2010, when they reached the $810 million mark, though they seesawed higher that year from $671 million in 2009. But Boston Scientific is phasing out Promus and stopped paying royalties to Abbott ($ABT) as of the 2012 second quarter when the companies' Promus supply arrangement came to an end. Why the change? Boston Scientific wanted to maximize its revenue and focus on stents it manufactures itself, which now include the Promus Element and Taxus stent systems. The company argued in its second-quarter regulatory filing that those successor products provide "a competitive advantage that has allowed us to maintain our leadership position in the U.S. drug-eluting stent market." We'll see for 2012, but for now, the jury's still out.
Abbott to cut 700 jobs as Promus sales decline